Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 20;11:1758835919876828. doi: 10.1177/1758835919876828

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 5. — Baseline and restaging 6 months following ADT in a patient with grade group IV prostate cancer. ⁶⁸Ga-PSMA PET/CT (axial fused), SPECT/CT bone scan (axial fused) and CT scans centred on a spinous process osseous metastasis are shown. At baseline, the metastasis is seen on PSMA PET/CT and bone SPECT/CT but not CT. At 6 months, a complete biochemical response (PSA < 0.1 ng/ml) was achieved correlating with complete response on PSMA PET/CT. The bone SPECT/CT, however, was stable and the CT demonstrated a ‘new’ sclerotic lesion. The bone scan and CT are not true reflective of disease status at 6 months.

ADT, androgen-deprivation therapy; CT, computed tomography; PET, positron-emission tomography; PSA, prostate-specific antigen; PSMA, prostate-specific-membrane antigen; ⁶⁸Ga-PSMA, gallium-68-labelled prostate-specific-membrane antigen; SPECT, single-photon-emission computed tomography.